“It’s pronounced nuc-ul-ophosmin” “Nucleophosmin”. “Noo-clee-o-phosmin”. FLT3-ITD got you In The Dumps? Have a Total Knowledge Deficit about TKD mutations? Struggling with the A-B-Cs of NPM1 mutations? Want to know how a cat sarcoma is somehow related to AML? Join the Bloody Minded Crew as they flit about the laboratory looking at the structure of FLT3 and NPM1, what these proteins usually do and how we test for mutations in the advanced myeloid episode.

== Edit 6/5/26 = We've been made aware that strictly speaking the current MANE approved transcript for NPM1.1 has only 11 exons and therefore the mutations are best to be considered in Exon 11 as opposed to exon 12 - in contrast to what we said. ==

Timestamps

0:52 - Bloody Minded issues a formal apology
2:40 - Introducing molecular chaperones
5:05 - What even NPM1?
9:30 - Functions of NPM1
10:55 - Molecular biology of NPM1 in disease
15:42 - Why the subtypes are important
19:53 - NPM1 prognosis
21:35 - MRD testing in NPM1
25:52 - NPM1 summary
27:13 - Intro to FLT3
28:30 - Mandatory FLT3 history
36:28 - FLT3 pathogenesis
37:37 - FLT3 structure, ITD vs TKD
41:16 - The juxtamembrane domain
42:53 - Prognostic features in FLT3
44:17 - TKD mutations
46:26 - FLT3 in the lab
50:30 - Take home messages

Support the show

Check out show notes, additional references and (sometimes) extra content at www.bloodyminded.com.au